ArticleMicrobiology spectrum2026
Multi-omics insights into growth impairment mechanisms in children with persistent diarrhea.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
This study aimed to elucidate the key mechanisms underlying short stature with pediatric persistent diarrhea in children (PDC) and to propose an integrated model linking the butyrate-producing gut microbial niche, short-chain fatty acids (SCFAs), Th17/Treg balance, the growth hormone-insulin-like growth factor 1 (GH-IGF-1) axis, and growth regulation. Samples from healthy controls (HCs), PDC patients without short stature (PDC-NS), and PDC patients with short stature (PDC-S) were analyzed using multi-omics profiling and machine learning-based predictive modeling. The results showed that PDC-S patients exhibited disruption of core butyrate-producing bacterial communities and related metabolic pathways, markedly reduced fecal butyrate levels, systemic Th17/Treg imbalance characterized by a pro-inflammatory state, and dual suppression of receptor- and ligand-level components of the GH-IGF-1 axis. Multi-omics machine learning identified a five-factor risk prediction panel composed of metabolic, immune, and endocrine markers, while causal inference further established butyrate as a central regulator of growth. Mouse experiments further validated that combined intervention with butyrate, IMPORTANCE: The research conducted in this study holds significant implications for improving the understanding and treatment of stunted growth with persistent diarrhea in children (PDC). By unraveling the intricate pathways linking gut microbiota, immune responses, and growth hormone regulation, the study sheds light on the underlying mechanisms contributing to stunting in these vulnerable populations. The identification of key factors, such as butyrate-producing bacteria and the Th17/Treg balance, not only enhances our comprehension of PDC-related growth impairment but also offers a promising avenue for targeted interventions. The proposed integrated mechanistic model and intervention strategy pave the way for precision therapies tailored to address the specific biological mechanisms at play, potentially leading to more effective and personalized treatments for children suffering from PDC-associated stunting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.